Author: Qiu, Yingshan; Lam, Jenny K. W.; Leung, Susan W. S.; Liang, Wanling
Title: Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside Document date: 2016_9_20
ID: 04pp3lv0_28
Snippet: Lung cancer is a leading cause of cancer death in the world. The mainstay of treatment is chemotherapy, which is indicated for around 70% of newly diagnosed patients with local and advanced metastatic disease [93] . Other treatment options include surgery and radiotherapy [94] . Angiogenesis inhibitors [95] and epidermal growth factor receptor (EGFR) inhibitors [96, 97] are new medications licensed for the treatment of lung cancer. Despite variou.....
Document: Lung cancer is a leading cause of cancer death in the world. The mainstay of treatment is chemotherapy, which is indicated for around 70% of newly diagnosed patients with local and advanced metastatic disease [93] . Other treatment options include surgery and radiotherapy [94] . Angiogenesis inhibitors [95] and epidermal growth factor receptor (EGFR) inhibitors [96, 97] are new medications licensed for the treatment of lung cancer. Despite various treatment options, the prognosis of lung cancer is poor. The major problems of chemotherapy are toxicity, lack of specificity and drug resistance [98] . In recent years, pulmonary delivery of RNAi molecules is being explored as a new treatment for lung cancer [99] . Genes that are associated with tumor cell growth and drug resistance are potential targets. Table 2 summarizes some recent in vivo studies of pulmonary RNAi delivery for lung cancer treatment.
Search related documents:
Co phrase search for related documents- metastatic disease and treatment mainstay: 1
- new treatment and potential target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- new treatment and pulmonary delivery: 1
- new treatment and recent year: 1, 2
- new treatment and treatment mainstay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- new treatment and treatment option: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- new treatment and vivo study: 1, 2, 3, 4
- new treatment and world cancer death: 1
- potential target and recent year: 1
- potential target and RNAi delivery: 1
- potential target and treatment mainstay: 1
- potential target and treatment option: 1, 2, 3, 4
- potential target and vivo study: 1, 2, 3, 4
- potential target and world cancer death: 1
- potential target and world cancer death leading cause: 1
- pulmonary delivery and RNAi delivery: 1, 2, 3, 4, 5, 6, 7, 8
- pulmonary delivery and vivo study: 1, 2
- recent year and treatment mainstay: 1
- recent year and treatment option: 1, 2
Co phrase search for related documents, hyperlinks ordered by date